Twelve-Week Treatment With Liraglutide as Add-on to Insulin in Normal-Weight Patients With Poorly Controlled Type 1 Diabetes: A Randomized, Placebo-Controlled, Double-Blind Parallel Study
Article Information
vol. 38 no. 12 2250-2257
PubMed
Published By
Print ISSN
Online ISSN
History
- Received May 16, 2015
- Accepted September 22, 2015
- Published in print November 24, 2015.
- Published online ahead of print October 20, 2015.
Article Versions
- Previous version (October 20, 2015 - 08:34).
- You are viewing the most recent version of this article.
Copyright & Usage
© 2015 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered.
Author Information
- Christian S. Frandsen1,2⇑,
- Thomas F. Dejgaard1,3,
- Jens J. Holst2,4,
- Henrik U. Andersen3,
- Birger Thorsteinsson5 and
- Sten Madsbad1,2
- 1Department of Endocrinology, Hvidovre Hospital, University of Copenhagen, Hvidovre, Denmark
- 2The Novo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen, Copenhagen, Denmark
- 3Steno Diabetes Center, Gentofte, Denmark
- 4Faculty of Health and Medical Sciences, Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark
- 5Department of Nephrology, Cardiology and Endocrinology, Nordsjællands Hospital, University of Copenhagen, Hillerød, Denmark
- Corresponding author: Christian S. Frandsen, frandsenmail{at}gmail.com or christian.seerup.frandsen{at}regionh.dk.
Statistics from Altmetric.com
Article usage
In this Issue
December 2015, 38(12)
Twelve-Week Treatment With Liraglutide as Add-on to Insulin in Normal-Weight Patients With Poorly Controlled Type 1 Diabetes: A Randomized, Placebo-Controlled, Double-Blind Parallel Study
